Jci_page_head_homepage_01 Jci_page_head_homepage_02
Yanqing Gong, Erika Hart, Aleksey Shchurin, Jane Hoover-Plow
Published in Volume 118, Issue 9
J Clin Invest. 2008; 118(9):3012–3024 doi:10.1172/JCI32750
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 6
Macrophages require MMP-9 in vivo to migrate across peritoneal tissue, and actMMP-9 rescues impaired macrophage migration in Plg–/– mice.

(A) Macrophage migration in Mmp9+/+ or Mmp9–/– mice and in Plg+/+ mice treated with control IgG or anti–MMP-9 antibody was measured 72 hours after thioglycollate injection (n = 5–7). Inset, gelatin zymograph of PLF from Plg+/+ mice treated with IgG or MMP-9 antibody shows that the MMP-9 neutralization abolishes MMP-9 activation. (BJ) Before thioglycollate injection, mice were treated with PBS, proMMP-9, and actMMP-9, and 48 hours after thioglycollate injection, peritoneal lavage and tissue were collected. Results are from 3 independent assays (n = 5–7). (B) actMMP-9 restores the suppressed macrophage recruitment to the peritoneal cavity in Plg–/– mice. (CH) Collagen IV (collagen IV antibody) and macrophage (Mac-3 antibody) immunostaining in Plg–/– mice. Arrowheads indicate mesothelial layer; asterisk indicates macrophage accumulation area. Original magnification (C and D), ×100; insets, ×200. Original magnification (EH), ×200; insets, ×400. (I) Macrophage distribution expressed as percentage of total sample area in peritoneal tissue. (J) Soluble collagen IV degradation products in PLF of Plg–/– mice. *P < 0.05, **P < 0.01.